Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Arthritis Rheumatol 2017;69:376–86
One of the challenges of treating SLE is the limited efficacy and poor tolerability of current therapies.
In this Phase 2b study, Furie at el assess the safety and efficacy of anifrolumab – a type I interferon receptor agonist – versus placebo in patients with moderate-to-severe SLE. The percentage of patients with an SRI(4) response at Week 24 was greater in the anifrolumab groups versus the placebo group, with a greater effect size in patients with a high IFN signature at baseline. This study indicates that targeting IFN receptors is a promising therapeutic approach in patents who have had a poor response to currently available therapies.